By LEE FERRAN Just a month after being diagnosed with breast cancer, actress Christina Applegate is perfectly healthy and cancer-free, she told Robin Roberts of "Good Morning America" in an exclusive interview that will air Tuesday.

DALLAS, Aug. 18 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI Pharma, Amgen and Genentech. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radiation treatments, and has already received marketing allowance from the U.S. Food and Drug Administration. Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon commercialization of MuGard. Milestone expects to launch MuGard in the US early in the first quarter of 2009.

DALLAS, Aug. 18 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI Pharma, Amgen and Genentech. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radiation treatments, and has already received marketing allowance from the U.S. Food and Drug Administration. Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon commercialization of MuGard. Milestone expects to launch MuGard in the US early in the first quarter of 2009.

Members of minority groups who perceive racial discrimination from their health care providers are less likely to be screened for breast or colon cancers, according to a recent study published in the journal Cancer Epidemiology, Biomarkers and Prevention, Reuters Health reports.

BETHESDA, Md., Aug. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call this morning, Monday, August 18, 2008, at 10:00 a.m. Eastern Time (4:00 p.m. Central European Time) to discuss the blinatumomab data that were published in the Journal SCIENCE on August 15, 2008.

As part of the partnership, SuperValu stores support Action Cancer's Big Bus mobile service, which offers digital breast screening, men's health clinics, ...

FRANKLIN LAKES, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS), the nation's leading pharmacy benefit manager, announced it and the Food and Drug Administration (FDA) have entered into a research partnership to study genetic testing and the impact of genetics on the efficacy of prescription drugs. The announcement adds credence to the emerging science of personalized medicine and will expand the body of evidence for the consideration of personal genetics in how doctors prescribe drugs.

And the Women's Health Initiative, which was a very large federal study, that was reported in 2002, made that connection very clear," Dr. Allen continued. ...

You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report ...

CHICAGO, Aug. 15 /PRNewswire-USNewswire/ -- In November 1994, the Cancer Prevention Coalition and the Center for Constitutional Rights submitted a Petition to the FDA calling for "Cancer Labeling of Talc Products." Talc products are regularly used by up to 17% of women for genital hygiene.